Morningstar Investment Services LLC Decreases Stock Position in Sanofi (NASDAQ:SNY)

Morningstar Investment Services LLC cut its position in Sanofi (NASDAQ:SNY - Free Report) by 47.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,670 shares of the company's stock after selling 35,178 shares during the period. Morningstar Investment Services LLC's holdings in Sanofi were worth $2,200,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Cardinal Capital Management increased its holdings in shares of Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after purchasing an additional 199 shares during the period. Gradient Investments LLC increased its holdings in shares of Sanofi by 2.1% in the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock valued at $542,000 after purchasing an additional 200 shares during the period. Providence Capital Advisors LLC increased its holdings in shares of Sanofi by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after purchasing an additional 201 shares during the period. Perigon Wealth Management LLC increased its holdings in shares of Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after purchasing an additional 201 shares during the period. Finally, Beacon Financial Group increased its holdings in shares of Sanofi by 1.6% in the first quarter. Beacon Financial Group now owns 14,398 shares of the company's stock valued at $799,000 after purchasing an additional 222 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

SNY traded down $0.33 during trading on Friday, hitting $48.32. The company's stock had a trading volume of 1,652,894 shares, compared to its average volume of 2,318,942. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The business's fifty day simple moving average is $49.65 and its 200 day simple moving average is $52.11. The firm has a market capitalization of $118.50 billion, a price-to-earnings ratio of 17.26, a P/E/G ratio of 1.10 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period last year, the company earned $1.78 earnings per share. Sanofi's quarterly revenue was down 11.0% compared to the same quarter last year. On average, equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of research reports. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. BNP Paribas began coverage on Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. Finally, Morgan Stanley set a $56.00 target price on Sanofi in a report on Monday, June 2nd. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.